The controversy over Novartis’ ultra-pricey gene therapy Zolgensma has intensified after it allegedly refused to supply the one-off therapy to a sick toddler in Belgium on compassionate gro
Novartis’ Cosentyx could be heading for a fourth indication after the company published late-stage trial data showing it improved symptoms in patients with non-radiographic axial spondyloar
Eagerly awaited trial data from Amgen’s latest KRAS-targeting cancer drug AMG 510 emerged over the weekend – and the results have received broadly positive reviews.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
